Discover leading companies driving innovation in the biotechnology sector across Spain. This ranking highlights groundbreaking firms specializing in areas such as pharmaceuticals, diagnostics, genomics, bioinformatics, and agricultural biotechnology. Explore key players contributing to scientific advancements, research and development (R&D), and the growing life sciences industry within the Spanish market. Ideal for investors, industry professionals, and those interested in cutting-edge biotech solutions and emerging technologies.
Eurofins Ingenasa has over 30 years of specialization in the development and manufacturing of veterinary diagnostic and food safety kits. Its commitment to research and innovation keeps it as one of the best biotechnology companies in Madrid in 2026.
Vivia Biotech is a medical diagnostics company that develops ex vivo assays for hematological neoplasms. Its innovation in the diagnosis of complex diseases makes it one of the most relevant biotech startups for 2026.
Biolan Microbiosensores is recognized for its specialization in biosensors for food safety and quality assessment. It has been highlighted as one of the best biotech startups in Spain to follow in 2026.
OXOlife focuses on the development of an innovative reproductive drug to improve female fertility. Its inclusion in the list of the best biotech startups to follow in 2026 underlines its potential and relevance in the field of reproductive health.
Cebiotex stands out for its electrospun nanofiber technology for drug delivery and its contract research offering. Its recognition as one of the best biotech startups in Spain to follow in 2026 validates its innovative approach.
All the rankings you can imagine
Thousands of verified votes to discover the best. Your vote here counts
Founded in 2006, 3P Biopharmaceuticals is an established company in the manufacturing and biomedical and biopharmaceutical engineering services. Its inclusion in the list of biotech startups to follow in 2026 highlights its continued relevance and innovation in the sector.
DNActive specializes in personalized genetic testing for predisposition to major diseases. Its focus on preventive and personalized medicine positions it as a key biotech startup to follow in 2026.
SpliceBio is a gene therapy company that uses an innovative intein platform technology to treat incurable genetic diseases. Its inclusion in the list of biotech startups to follow in 2026 underscores its transformative potential in medicine.
Evolving Therapeutics works on phage-based therapies to combat multi-drug resistant bacteria, a global health challenge. Its inclusion in the list of Valencian startups to follow in 2026 highlights its relevance in the fight against antimicrobial resistance.
Arthex Biotech specializes in RNA-based therapies for rare diseases, such as myotonic dystrophy type 1. Its recent $45 million funding round and the advancement of its lead candidate towards clinical phases solidify its position as a leader in biotechnology.
Progevita focuses on regenerative therapies, with a platform based on frontier research and early clinical validation. Its new trials and patents in development make it an innovative biotech company to follow in 2026.
Oryzon Genomics is a clinical-stage biopharmaceutical company developing epigenetic therapies. The EMA's approval for a Phase Ib study in sickle cell disease and the submission of a Phase III protocol to the FDA in 2025 demonstrate its significant progress.
Anaconda BioMed, a medical device company, received CE mark for its ANA5 funnel catheter in 2025 and published study results. These advances solidify its position as an innovative company in the medical biotechnology sector.
Quibim, specializing in medical image analysis, presented publications at ASCO 2025 and obtained FDA approval for its QP-Prostate CAD. These milestones demonstrate its leadership in the use of artificial intelligence for oncological diagnosis.
Ona Therapeutics focuses on cancer treatment and has achieved a strategic partnership with REVEAL Genomics and a Series A funding round in 2025. These advances position it as a promising biotech company in the fight against cancer.
Amets Biotechnology, a startup from the CEIN ecosystem, won second prize at the Innovator's Pitch Challenge (IPC) at RESI Europe in March 2026. This recognition underscores its innovative potential and its visibility in the European biotech field.
Darwin Biomed, a startup from the CEIN ecosystem, participated in three international health and biotechnology forums in March 2026. This international activity demonstrates its commitment to innovation and its search for collaborations and growth opportunities.
Aortyx proposes an innovative solution for aortic diseases with a biodegradable patch that repairs the artery. Its electrospinning technology and ultrasound visibility make it a prominent biotechnology company in the field of medical devices.